Saturday 17 October 2026
Export VTGN’s income statement to Excel — free account
VistaGen Therapeutics, Inc.
VTGN Healthcare Biotechnology
VistaGen Therapeutics, Inc.’s revenue for fiscal 2026 (year ended March 2026) was $1.3 million, up 161.1% from fiscal 2025. In the quarter to June 2026, revenue grew 504.9%, EPS grew 36.2% and free cash flow grew 22.2%, each against the same quarter a year earlier.
0.20
0.01
−4.76%
Follow VTGN
| Mar '17 | Mar '18 | Mar '19 | Mar '20 | Mar '21 | Mar '22 | Mar '23 | Mar '24 | Mar '25 | Mar '26 | |
|---|---|---|---|---|---|---|---|---|---|---|
Piotroski F-Score |
— | — | — | — | — | — | — | — | 2 | 3 |
P/E ratio |
0.00 | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z-Score |
(58.82) | — | — | — | 4.47 | 8.77 | (28.58) | 2.76 | (4.64) | (16.79) |
P/S ratio |
7.67 | — | — | — | 78.34 | 221.39 | 0.00 | 98.23 | 158.83 | 17.10 |
P/FCF ratio |
0.00 | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
(139.49) | — | — | — | 4.25 | (3.41) | (63.98) | 7.76 | (9.52) | (34.55) |
P/Operating CF |
(11.40) | — | — | — | (34.70) | (15.75) | (3.35) | (14.96) | (7.67) | (1.34) |
P/B ratio |
24.10 | — | — | — | 1.99 | 3.79 | 2.07 | 0.91 | 1.10 | 0.61 |
Price to Tangible BV |
24.10 | — | — | — | 1.99 | 3.79 | 2.07 | 0.91 | 1.10 | 0.61 |
EV/Sales |
10.48 | — | — | — | 39.25 | 169.78 | (73.68) | (5.96) | 10.33 | (12.13) |
EV/EBITDA |
0.00 | — | — | — | 0.00 | 0.00 | 0.00 | 0.19 | 0.00 | 0.21 |
EV/Operating CF |
(2.77) | — | — | — | (7.61) | (4.16) | (0.34) | 0.25 | (0.12) | 0.23 |
EV/FCF |
(2.69) | — | — | — | (7.43) | (4.14) | (0.33) | 0.25 | (0.12) | 0.23 |
Quick Ratio |
2.14 | 7.12 | 4.78 | 0.49 | 24.61 | 11.82 | 3.64 | 23.26 | 6.38 | 3.55 |
Current Ratio |
2.47 | 7.56 | 4.87 | 0.57 | 24.86 | 12.32 | 3.83 | 23.55 | 6.51 | 3.67 |
Net Debt/EBITDA |
0.29 | 0.73 | 0.54 | 0.07 | 5.79 | 1.43 | 0.28 | 3.62 | 1.43 | 0.63 |
Debt/Assets |
0.32% | 0.08% | 0.04% | 0.05% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Debt/Equity |
0.02 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.53 | 0.00 | 0.00 | 0.00 | 0.02 | 0.01 | 0.00 | 0.01 | 0.00 | 0.02 |
Operating CF/Net income |
0.62 | 0.58 | 0.56 | 0.72 | 0.29 | 0.93 | 0.84 | 0.88 | 0.82 | 0.95 |
Capex/Depreciation |
(1.73) | (0.02) | (0.82) | 0.00 | (2.34) | (1.31) | (1.63) | (0.48) | 0.80 | 0.44 |
Interest Coverage |
(2,227.93) | (1,595.46) | (3,069.54) | 691.08 | (1,228.34) | (2,400.95) | (1,204.63) | — | — | — |
| 980.11% | (414.00%) | (367.99%) | (3,294.60%) | (98.14%) | (62.17%) | (154.30%) | (46.47%) | (55.68%) | (131.59%) | |
| (494.41%) | (207.80%) | (203.48%) | (222.78%) | (74.21%) | (53.25%) | (123.78%) | (40.57%) | (49.44%) | (104.86%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(506.06%) | (159.39%) | (230.95%) | 2,245.30% | (42.19%) | (74.20%) | (440.83%) | (25.32%) | (73.52%) | (201.55%) |
Average Days of Receivables |
0.00 | — | 0.00 | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
416.30% | 0.00% | 0.00% | 0.00% | 1,094.60% | 3,193.06% | (19,549.34%) | 1,881.77% | 8,101.85% | 4,332.07% |
Selling, General and Administrative Expense of Revenue |
503.58% | 0.00% | 0.00% | 0.00% | 651.45% | 1,215.62% | (6,459.91%) | 1,321.71% | 3,515.23% | 1,451.62% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
248.54% | 0.00% | 0.00% | 0.00% | 211.67% | 313.89% | (1,469.60%) | 205.08% | 887.86% | 314.97% |
Graham Net Nets |
0.02 | — | — | — | 0.48 | 0.25 | 0.34 | 1.07 | 0.88 | 1.56 |
Graham Number |
0.00 | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(81.20%) | — | — | — | (18.33%) | (19.37%) | (238.82%) | (38.33%) | (66.40%) | (321.05%) |
Free Cash Flow Yield |
(50.87%) | — | — | — | (6.74%) | (18.52%) | (199.30%) | (24.77%) | (54.78%) | (306.82%) |
Revenue per Share |
4.98 | 0.00 | 0.00 | 0.00 | 0.38 | 0.17 | (0.03) | 0.06 | 0.02 | 0.03 |
Operating CF per Share |
(28.96) | (19.59) | (15.27) | (10.79) | (4.21) | (6.86) | (7.14) | (1.33) | (1.36) | (1.74) |
Capex per Share |
(0.95) | 0.00 | (0.18) | 0.00 | (0.10) | (0.03) | (0.03) | 0.00 | (0.01) | 0.00 |
Free Cash Flow per Share |
(29.91) | (19.59) | (15.46) | (10.79) | (4.31) | (6.89) | (7.17) | (1.34) | (1.37) | (1.75) |
Cash per Share |
11.65 | 22.44 | 13.77 | 0.93 | 35.95 | 10.32 | 2.39 | 6.16 | 2.61 | 1.19 |
Shareholders Equity per Share |
2.46 | 14.95 | 7.44 | (3.92) | 32.07 | 9.81 | 1.74 | 5.90 | 2.28 | 0.93 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.46 | 14.95 | 7.44 | (3.92) | 32.07 | 9.81 | 1.74 | 5.90 | 2.28 | 0.93 |
Free Cash Flow |
(7.50) | (9.06) | (14.70) | (15.76) | (12.35) | (45.46) | (49.93) | (25.87) | (42.29) | (66.59) |
Working Capital |
2.01 | 9.56 | 10.83 | (1.19) | 99.93 | 65.23 | 12.93 | 115.55 | 69.46 | 34.15 |
Capital Expenditures |
(0.24) | 0.00 | (0.17) | — | (0.28) | (0.20) | (0.21) | (0.06) | (0.19) | (0.15) |
Net Current Asset Value |
0.28 | 6.66 | 6.69 | (9.92) | 87.81 | 61.07 | 8.50 | 111.31 | 68.13 | 33.90 |
EV/EBIT |
0.00 | — | — | — | 0.00 | 0.00 | 0.00 | 0.19 | 0.00 | 0.21 |
Capex to Sales |
0.19 | 0.00 | 0.00 | — | 0.25 | 0.18 | (0.93) | 0.06 | 0.39 | 0.12 |
Price to Operating Income |
0.00 | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
0.48 | 0.39 | 0.67 | 0.56 | 0.32 | 0.37 | 0.26 | 0.29 | (0.50) | (0.81) |
Cash ROIC |
(211.36%) | (52.36%) | (72.85%) | 360.46% | (6.33%) | (34.22%) | (173.86%) | (11.08%) | (28.03%) | (82.28%) |
Accounts Receivable Turnover |
0.00 | — | 0.00 | — | 6.40 | 5.86 | (0.74) | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | 0.00 | 0.00 | 0.00 | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
— | — | 0.20 | — | 0.17 | 0.19 | 0.31 | — | — | — |
Average Payables |
0.90 | 1.03 | 1.13 | 1.45 | 1.34 | 1.80 | 2.62 | 2.01 | 1.10 | 1.09 |
Average Assets |
2.35 | 7.50 | 12.65 | 9.89 | 57.03 | 91.46 | 47.87 | 72.37 | 104.00 | 66.45 |
Average Common Equity |
(1.19) | 3.76 | 6.99 | 0.67 | 43.12 | 78.34 | 38.40 | 63.18 | 92.34 | 52.96 |
Columns are period end dates